Back to Agenda
Session 3: Opportunities for CMC in Accelerated Development Programmes Part 2
Session Chair(s)
Susanne Ausborn, PhD
Global Head International Regulatory Policy
Roche, Switzerland
Frank Montgomery, PhD
Global Head Regulatory CMC, GRAPSQA
AstraZeneca, United Kingdom
Session 3: Opportunities for CMC in Accelerated Development Programmes Part 2
Speaker(s)
Panel Discussion and Q&A, with the participation of the Regulators present at Session 1 and the Industry Representatives from Session 2
Ghadeer Al-Sheikh Salem
Jordan Food and Drug Administration, Jordan
Head, Originator and Biological Drugs Division, Registration Department
Dmitriy Rozdestvensky, MD, PhD
Eurasian Economic Commission, Russian Federation
Head, Division for Coordination of Common Market for Drugs and Medical Devices F
Veronika Jekerle, PhD, RPh
European Medicines Agency, Netherlands
Head of Pharmaceutical Quality
Bernardo Moreira
Brazilian Health Regulatory Agency (ANVISA), Brazil
Second Directory Assessor (DIRE2)
Fabian Schwarb, PhD
Siegfried AG, Switzerland
Global Head Regulatory Affairs
T. Venkateshwaran, PhD
Merck & Co., Inc., United States
Vice President and Global Head CMC Biologics, Medical Devices and Comb
Florence Salmon
Novartis, Switzerland
Director Regulatory Affairs CMC
Have an account?